Although huge strides have been made with antiretroviral therapy (ART) and prevention since HIV was first reported 42 years ago, there is still not an effective preventive vaccine or a scalable cure for those living with HIV. But broadly neutralizing antibodies (bNAbs) look to be a further step down the pathway to a cure, speakers said during the International AIDS Society meeting held July 23 to 26 in Brisbane, Australia.

Characterized by periods of deep and profound depression alternating with periods of excessive mania mood swings with diminished sleep, bipolar spectrum disorder (BSD) affected an estimated 40 million people globally in 2019 in the U.S. with a major part of the problem attributed to delays in diagnosis including a mean time of 5-13 years. These delays in BSD diagnosis exert lifelong impacts including heightened suicide risk, relationship strains, impaired work/education performance, significant financial burdens and increased risk for cardiovascular disease.

Sandfly bites transmit the intracellular protozoan Leishmania to cause leishmaniasis that exhibits with clinical presentations ranging from a cutaneous ulcer to treatment-resistant lethal systemic disease (visceral leishmaniasis; VL). VL reportedly kills 20,000 to 30,000 every year according to the World Health Organization, where current medications are limited by side effects and evolving antibiotic resistance. Accordingly, there is a great need to develop alternatives.

Researchers from Anhui Medical University (AMU) presented data from a study that aimed to assess the role of gastrin-releasing peptide (GRP) and its receptor GRPR in acute kidney injury (AKI).

Researchers from Collaborations Pharmaceuticals Inc. recently reported the discovery and preclinical evaluation of a novel pleconaril-based molecule, 11526092, being develop as an antiviral agent against enteroviruses.